A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Trial Profile

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications Rhabdoid tumour; Synovial sarcoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Epizyme
  • Most Recent Events

    • 01 Nov 2017 According to an Epizyme media release, data from the study will be presented during a plenary session at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2017.
    • 30 Oct 2017 Interim results (n=46) from dose escalation cohorts of a Phase 1 pediatric study presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
    • 27 Oct 2017 Results presenteded in an Epizyme Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top